Acentage Pharma apresentará o progresso da droga contra o câncer na J.P. Morgan Healthcare Conference em São Francisco. Ascentage Pharma to present cancer drug progress at J.P. Morgan Healthcare Conference in San Francisco.

A Ascentage Pharma, uma empresa biofarmacêutica focada em terapias contra o câncer, apresentará seu progresso e planos futuros na J.P. Morgan Healthcare Conference em 16 de janeiro de 2025, em São Francisco. Ascentage Pharma, a biopharmaceutical company focused on cancer therapies, will present its progress and future plans at the J.P. Morgan Healthcare Conference on January 16, 2025, in San Francisco. A empresa, liderada pelo CEO Dr. Dajun Yang, tem um pipeline robusto de candidatos a medicamentos e colabora com grandes empresas farmacêuticas como Takeda, AstraZeneca e Pfizer. The company, led by CEO Dr. Dajun Yang, has a robust pipeline of drug candidates and collaborates with major pharmaceutical firms like Takeda, AstraZeneca, and Pfizer. A sua droga principal, olverembatinib, está incluída na lista nacional de reembolso de drogas da China. Its lead drug, olverembatinib, is included in China's national drug reimbursement list.